EU/3/13/1224

About

On 16 January 2014, orphan designation (EU/3/13/1224) was granted by the European Commission to Hope Pharmaceuticals, Ltd., United Kingdom, for sodium nitrite for the treatment of aneurysmal subarachnoid haemorrhage.

The sponsor’s address was updated in March 2019.

The sponsorship was transferred to Hope Pharmaceuticals Limited, Ireland, in August 2019.

Key facts

Active substance
Sodium nitrite
Disease / condition
Treatment of aneurysmal subarachnoid haemorrhage
Date of first decision
16/01/2014
Outcome
Positive
EU designation number
EU/3/13/1224

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Hope Pharmaceuticals Limited
Kyletelogue House
9 Cherrywood Park
Tallanstown
Dundalk A91 WV74
Co. Louth
Ireland 
E-mail: questions@hopepharm.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating